Deborah E. Citrin, M.D.

Senior Investigator

Radiation Oncology Branch

NCI/CCR

Building 10 - Hatfield CRC, Room B2-3500 Bethesda, MD 20892

301-496-5457

citrind@mail.nih.gov

Biography

Dr. Citrin is a graduate of the Duke University School of Medicine, where she also participated in the Howard Hughes Medical Student Research Fellow Program.  She completed an Internship in Internal Medicine at Washington Hospital Center and completed her residency training at the National Cancer Institute. She joined the Radiation Oncology Branch in 2005 and is currently a Senior Investigator in the Radiation Oncology Branch.  Dr. Citrin also serves as a CCR Deputy Director.

Selected Publications

  1. Chung SI, Horton JA, Ramalingam TR, White AO, Chung EJ, Hudak KE, Scroggins BT, Arron JR, Wynn TA, Citrin DE. IL-13 is a therapeutic target in radiation lung injury. Sci Rep. 2016;6:39714.

  2. Horton JA, Hudak KE, Chung EJ, White AO, Scroggins BT, Burkeen JF, Citrin DE. Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation. Stem Cells. 2013;31(10):2231-41.

  3. Citrin DE, Shankavaram U, Horton JA, Shield W 3rd, Zhao S, Asano H, White A, Sowers A, Thetford A, Chung EJ. Role of type II pneumocyte senescence in radiation-induced lung fibrosis. J Natl Cancer Inst. 2013;105(19):1474-84.

  4. Urick ME, Chung EJ, Shield WP 3rd, Gerber N, White A, Sowers A, Thetford A, Camphausen K, Mitchell J, Citrin DE. Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clin Cancer Res. 2011;17(15):5038-47.

  5. Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, Camphausen K, Citrin D. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res. 2009;15(9):3050-7.


This page was last updated on August 9th, 2021